

Alliance for Clinical Trials in Oncology Policies and Procedure

Table of Contents

1	Introduction.....	1-1
1.1	Specific aims.....	1-1
1.1.1	Scientific aims.....	1-1
1.1.2	Operational aims.....	1-2
1.1.3	Collaborative aims.....	1-2
1.2	Overview of program structure.....	1-4
1.2.1	Operations Center.....	1-6
1.2.2	Statistics and Data Management Program.....	1-7
1.2.3	Central Protocol Operations Program.....	1-8
1.2.4	Translational Research Program (TRP).....	1-9
1.2.5	Cancer Control Program.....	1-10
1.2.6	Procedure-Based Therapy Program.....	1-12
1.2.7	Member institutions.....	1-13
1.3	Committees.....	1-14
1.3.1	Scientific committees.....	1-14
1.3.2	Administrative committees.....	1-15
2	Institutional membership.....	2-1
2.1	Membership criteria.....	2-1
2.2	Applying for membership.....	2-2
2.3	Membership activation.....	2-3
2.3.1	Roster.....	2-3
2.3.1.1	NCI Tiers.....	2-3
2.3.2	Regulatory documentation.....	2-4
2.3.3	Financial documentation for institutions.....	2-4
2.4	Responsibilities of a main member.....	2-5
2.4.1	Communications.....	2-5
2.4.2	Electronic communication.....	2-5
2.4.3	Management of network data.....	2-6
2.4.4	Investigational drug handling.....	2-6
2.4.5	Human subject’s protection.....	2-6
2.4.6	Training.....	2-7
2.5	Continuing Alliance membership.....	2-8
2.5.1	Main members.....	2-8
2.5.2	Affiliates.....	2-9
2.6	Institutional roles and responsibilities.....	2-10

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

2.6.1	Main member principal investigator	2-10
	2.6.1.1 Network responsibilities	2-10
	2.6.1.2 Institutional responsibilities.....	2-10
2.6.2	Affiliate member principal investigator.....	2-11
2.6.3	Clinical research professionals	2-11
	2.6.3.1 Lead CRP.....	2-12
2.6.4	Withdrawn or terminated institutions	2-12
2.7	Office for Human Research Protections assurances	2-13
	2.7.1 Assurances.....	2-13
	2.7.2 Reporting institutional assurance compliance.....	2-13
2.8	Institutional Review Boards.....	2-14
	2.8.1 Reporting and review requirements.....	2-14
	2.8.2 Federal record-keeping requirements for IRBs.....	2-15
2.9	Institutional retention of study records.....	2-16
2.10	Non-member Collaborators	2-17
2.11	Participation in AFT.....	2-18
2.12	AFT Membership Accrual Credits	2-20
3	Participants	3-1
3.1	Participant Categories	3-1
3.2	Membership and participant registration	3-3
	3.2.1 Applying for membership and registration	3-3
	3.2.2 Alliance person database	3-4
3.3	Traveling on official Alliance business	3-5
3.4	Individual scientific misconduct	3-6
	3.4.1 Receipt of allegations of scientific misconduct.....	3-6
	3.4.2 Processing of allegation within Alliance.....	3-7
	3.4.3 Investigation of the allegation.....	3-7
	3.4.4 Actions to be taken if allegation of scientific misconduct is proved.....	3-8
	3.4.5 Publication and retraction.....	3-8
	3.4.6 Actions against individuals	3-8
	3.4.7 Confidentiality.....	3-9

Alliance for Clinical Trials in Oncology Policies and Procedure

3.5	Conflict of interest	3-10
3.5.1	Introduction	3-10
3.5.1.1	Policy	3-10
3.5.1.2	Scope	3-10
3.5.1.3	Disclosure	3-10
3.5.1.4	Management of De Minimus and Maxium Thresholds	3-11
3.5.1.5	Training.....	3-11
3.5.1.6	Alliance Member Responsibilities.....	3-11
3.5.1.7	Roles within the Alliance.....	3-11
3.5.2	Decisions on matters of conflict of interest.....	3-16
3.5.3	Review of Disclosure Statements	3-22
3.5.4	Actions on conflict of interest.....	3-22
3.5.5	Penalties for failure to observe the conflict of interest policy	3-22
3.5.6	Public disclosure	3-22
3.5.7	Record retention.....	3-22
3.5.8	Reporting Financial Conflicts of Interest (FICO).....	3-22
3.5.9	Alliance Conflict of Interest Committee.....	3-23
	End of Chapter Notes	3-24
4	Committees.....	4-1
4.1	Committees and their function in Alliance.....	4-1
4.1.1	Disease committees	4-1
4.1.2	Discipline committees	4-1
4.1.3	Modality committees	4-1
4.2	How to form a committee	4-2
4.3	Committee membership.....	4-3
4.4	Roles and responsibilities in committees.....	4-4
4.4.1	Committee chair nomination and approval.....	4-4
4.4.2	Committee chair nomination process.....	4-4
4.4.3	Committee chair responsibilities	4-4
4.4.3.1	Administration	4-4
4.4.3.2	Protocol development and management.....	4-6
4.4.3.3	Publications.....	4-7
4.4.3.4	Intergroup collaborations	4-7
4.4.3.5	Finances	4-7
4.4.4	Committee vice chairs.....	4-8

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

4.4.5	Subcommittee chairs/cadre leaders.....	4-9
4.4.6	Committee members	4-9
4.5	Electing Executive Committee members	4-10
5	Meetings	5-1
5.1	Group Meetings	5-1
5.1.1	Attendance	5-1
5.1.2	Travel funding for group meetings	5-2
5.1.3	Study accrual reports and publications	5-2
5.2	Identification of funded travelers and expense reports	5-3
5.2.1	Committee member funding and roster updates.....	5-3
5.2.2	Travel funding notification	5-3
5.2.3	Expense reports	5-3
5.3	Continuing Education (CE) Credit.....	5-4
5.3.1	Continuing Education (CE) Requirements.....	5-4
5.3.2	Continuing Education (CE) Credit Certificates.....	5-4
6	Study protocol.....	6-1
6.1	Study types.....	6-1
6.1.1	Treatment studies	6-1
6.1.2	Non-treatment studies	6-1
6.1.2.1	Companion and sub studies.....	6-1
6.2	Study participation... ..	6-3
6.2.1	Limited access studies	6-3
6.2.2	Credentialing	6-3
6.2.3	Non-Alliance members.....	6-3
6.3	Study team roles and responsibilities	6-4
6.3.1	Study Chair.....	6-4
6.3.1.1	Moving study chair to a non-Alliance institution... ..	6-4
6.3.1.2	Replacing study chair.....	6-5
6.3.2	Study co-chair.....	6-5
6.3.2.1	Moving study co-chair to a non-Alliance institution... ..	6-5
6.3.2.2	Replacing study co-chair.....	6-5
6.3.3	Committee chair	6-5
6.3.4	Primary statistician.....	6-6
6.3.4.1	Primary statistician	6-6
6.3.4.2	Secondary statistician.....	6-6
6.3.5	Data managers	6-6
6.3.6	Protocol coordinator	6-7
6.3.7	Executive officer.....	6-7

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

6.4	Protocol development	6-8
6.4.1	Protocol numbering	6-8
6.4.2	Concept	6-9
6.4.2.1	Concepts other than translational research and data-only requests	6-9
6.4.2.2	Concepts containing data-only requests	6-10
6.4.3	Developing the protocol.....	6-10
6.4.3.1	Communications post-SCRC and NCI concept approval	6-10
6.4.3.2	Protocol authoring.....	6-11
6.4.3.3	Determining the trial participant eligibility criteria	6-11
6.4.3.4	Inclusion of women and minorities.....	6-11
6.4.3.5	Determining the trial participant follow-up period.....	6-12
6.4.3.6	External protocol review	6-12
6.4.4	Developing case report forms	6-12
6.4.4.1	Determining data to be collected.....	6-13
6.4.4.2	Making use of standard Alliance forms.....	6-13
6.4.4.3	Using Translated Patient-Reported Questionnaires	6-13
6.4.4.4	Using copyrighted forms	6-14
6.4.4.5	Forms design	6-14
6.4.4.6	Forms review and approval.....	6-15
6.4.4.7	Forms revision.....	6-15
6.4.5	Participation in studies led by other Lead Protocol Organizations.....	6-15
6.5	Activating a study.....	6-16
6.6	Waivers	6-17
6.6.1	Eligibility waivers.....	6-17
6.6.2	Other waivers.....	6-17
6.7	Updating a study.....	6-18
6.7.1	Revisions and amendments	6-18
6.8	Suspending a study	6-19
6.9	Unblinding trial participants	6-20
6.9.1	Emergency unblinding.....	6-20
6.9.2	Protocol specific unblinding.....	6-20
6.9.3	Elective unblinding.....	6-20
6.9.4	Unblinding for Regulatory Reporting.....	6-21
6.10	Closing a study.....	6-22
6.10.1	Procedures for closing a study.....	6-22
6.10.2	Notifying patients about early closure of clinical trials.....	6-22
6.11	Release of data.....	6-23
6.11.1	Studies monitored by the DSMB	6-23
6.11.2	Studies not monitored by the DSMB.....	6-23

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

6.11.2.1	Appeals process.....	6-23
6.12	Completing a study.....	6-24
6.12.1	Archiving paper records.....	6-24
6.12.2	Archiving study database.....	6-24
6.12.3	Access to data for completed studies.....	6-24
6.13	Terminating a study.....	6-25
6.14	Study Termination with the Local IRB.....	6-26
6.15	Retrospective data collection from closed or completed studies.....	6-27
7	Patient registration.....	7-1
7.1	Authorization of institutions to register patients.....	7-1
7.1.1	Limited access studies.....	7-1
7.2	Authorization of site personnel to register patients.....	7-2
7.3	Credentialing.....	7-3
7.4	Confirming patient eligibility.....	7-4
7.5	Procedures to register patients to Alliance studies.....	7-5
7.5.1	Pre-registration.....	7-5
7.5.2	Multiple-Step Registration.....	7-5
7.6	Procedure to register patients to intergroup studies.....	7-6
8	Data management.....	8-1
8.1	Data submission.....	8-1
8.1.1	Competing Forms.....	8-1
8.1.1.1	Alliance general instructions: all forms (electronic CRFs and paper forms).....	8-1
8.1.1.2	Instructions for forms submitted during treatment/intervention and follow-up.....	8-1
8.1.2	Submission of data forms.....	8-3
8.1.2.1	General data submission instructions.....	8-3
8.1.2.2	Registered patients who never receive treatment/intervention.....	8-4
8.1.2.3	Transfer of patient to another institution.....	8-4
8.1.2.4	Refusal for further protocol treatment/intervention.....	8-5
8.1.2.5	Protocol non-compliance.....	8-5
8.1.2.6	Withdrawn consent for all future protocol data collection.....	8-5
8.1.2.7	Confirmation of lost to follow-up status.....	8-6
8.1.2.7.1	Procedure for confirming a patient is lost to follow-up.....	8-6
8.1.2.7.2	If a lost patient is found.....	8-7
8.1.3	Submission of samples, specimens, and modality materials.....	8-7

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

8.1.4	Submission of samples for studies led by other Lead Protocol Organizations	8-7
8.2	Receipt and distribution of data forms by SDMC	8-8
8.3	Quality assurance performed by Data Management Unit	8-9
8.3.1	Quality checks of on-study and eligibility data	8-9
8.4	Alliance case evaluation process	8-10
8.4.1	Objectives	8-10
8.4.2	Studies requiring case evaluation	8-10
8.4.3	Case evaluation form	8-11
8.4.3.1	Patient summary report	8-11
8.4.4	Data Access	8-11
8.4.5	Study Chair Adherence to Policy	8-12
9	Information systems	9-1
9.1	Member information	9-1
9.1.1	Member account request and setup	9-1
9.1.1.1	Individual institution members	9-2
9.1.2	Institution registration	9-2
9.1.3	Alliance application accounts	9-2
9.1.4	User names and passwords	9-2
9.1.5	Roles and permissions	9-2
9.1.6	System availability	9-3
9.1.7	User support	9-3
9.1.7.1	Alliance Service Center	9-3
9.2	SMU/ISU operations	9-5
9.2.1	Software development	9-5
9.2.2	Documentation policies	9-6
9.2.3	Technology selection and change management	9-6
9.2.4	Usage of computing resources for Alliance Staff	9-7
9.2.5	Security	9-7
9.2.6	Backups and data retention	9-10
9.2.7	Disaster recovery	9-11
10	Publications Committee charter and mission guidelines	10-1
10.1	Data ownership	10-1
10.2	Committee members	10-2
10.3	Group Review members	10-3
10.4	Abstract and manuscript preparation	10-4
10.4.1	General principles	10-4
10.4.2	Cover page	10-5
10.5	Authorship	10-6

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

10.5.1.1	Publication on the primary study endpoint.....	10-6
10.5.1.2	Publication on a secondary (correlative) study.....	10-9
10.6	Abstract and manuscript timelines.....	10-14
10.6.1	Timelines for abstract and manuscript preparation	10-14
10.6.2	Delinquency in manuscript preparation.....	10-15
10.6.3	Timelines for review and revision of abstracts	10-15
10.6.4	Timelines for review and revision of manuscripts.....	10-16
10.6.5	Approval of abstracts and manuscripts.....	10-16
10.7	Abstract or manuscript submission to meeting or journal.....	10-17
10.8	Publication of abstract or manuscript.....	10-18
10.9	Publicizing Research Information	10-19
10.10	Summary of study results for the public	10-20
10.11	Public Access.....	10-21
10.11.1	Overview of methods for manuscript submission to PubMed Central.....	10-21
10.11.2	Deadlines to ensure compliance with NIH PAP by journal method	10-23
10.11.3	Author responsibilities based on journal methods	10-24
10.11.4	Resources for NIH Public Access Policy.....	10-28
10.11.5	Alliance Monitoring of Compliance with NIH Public Access Policy	10-28
10.12	Quick view of Alliance deadlines for authors.....	10-30
11	Alliance Biorepositories and Biospecimen Resource (ABBR) and Translational Research.....	11-1
11.1	ABBR Infrastructure and Oversight.....	11-1
11.1.1	ABBR	11-1
11.1.1.1	Alliance Biorepository at the Ohio State University	11-1
11.1.1.2	Alliance Hematological Malignancy Biorepository (HEME)	11-1
11.1.1.3	Alliance Lung Cancer Tissue Bank (LCTB).....	11-1
11.1.1.4	Alliance Biorepository at Washington University in St. Louis (WUSTL).....	11-1
11.1.1.5	Alliance Biorepository at Mayo Clinic (MAYO).....	11-1
11.2	Biorepository Functions.....	11-4
11.2.1	Biospecimen Collection.....	11-4
11.2.2	Storage.....	11-4
11.2.3	Processing.....	11-4
11.2.4	Quality Assurance.....	11-4
11.2.5	Regulatory Compliance.....	11-4
11.2.6	Distribution.....	11-5
11.2.7	Direct submission.....	11-5

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

11.2.8	ABBR support for different study types.....	11-5
11.2.8.1	Integral Biomarker Studies	11-5
11.2.8.2	Integrated (Embedded) Correlative Studies.....	11-6
11.2.8.3	Biobanking for Stand-alone Secondary Correlative Studies	11-6
11.3	Biospecimen Collection Funding	11-7
11.3.1	NCI U24 Biorepository Funding	11-7
11.3.2	Clinical Trial Budget.....	11-7
11.3.3	BIQSFP	11-7
11.3.4	Non-NCI Funding	11-7
11.3.5	Research Grants (Federal and Non-federal)	11-8
11.4	Correlative Science and Biospecimen Collection Protocol Development.....	11-9
11.5	Biospecimen Collection Policies.....	11-12
11.6	Biospecimen Processing and Storage Policies.....	11-13
11.7	Biospecimen Reporting and Tracking.....	11-14
11.8	Patient Consent, Confidentiality, and Regulatory Compliance	11-15
11.9	Biospecimen Pathology Review.....	11-18
11.10	Accessing Banked Biospecimens Overview	11-20
11.11	Stand-alone Secondary Biospecimen Use Studies.....	11-22
11.12	Data Generation, Ownership, and Publications	11-23
12	Investigational Products.....	12-1
12.1	Investigational Agent Accountability and Procurement	12-1
12.1.1	National Cancer Institute (NCI) Investigational Agents	12-1
12.1.2	Investigational Agents Distributed by the Alliance	12-1
12.1.3	Shipment of Investigational Agents	12-2
12.1.4	Use of Investigational Agents	12-2
12.1.5	Storage and Accountability of Investigational Agents.....	12-3
12.1.6	Deviation from Study Protocol.....	12-3
12.2	Investigational Devices Accountability and Procurement.....	12-4
12.2.1	Investigational Devices Distributed by the Alliance.....	12-4
12.2.2	Shipment of Investigational Devices.....	12-4
12.2.3	Use of Investigational Devices.....	12-4
12.2.4	Storage and Accountability of Investigational Devices.....	12-5
12.2.5	Deviation from Study Protocol.....	12-5
12.3	Investigational New Drug Applications.....	12-6
12.3.1	Investigational New Drug (IND).....	12-6
12.3.1.1	IND Required	12-6
12.3.1.2	IND Exemption	12-6

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

12.3.2	Investigational Device Exemption (IDE).....	12-6
12.3.3	FDA Reporting.....	12-6
13	Industry relations	13-1
13.1	Industry documents.....	13-1
13.1.1	Letter of Support	13-2
13.1.2	Protocol document.....	13-2
13.1.3	Letter Agreement for Provision of Financial Support.....	13-2
13.1.4	Memorandum of Understanding Regarding Drug, Device or Service Provision.....	13-3
13.2	Confidential and Proprietary Information.....	13-4
13.3	Data Ownership in the Context of Industry Collaboration.....	13-5
13.4	Standard Reporting to Industry Collaborators.....	13-6
13.5	Indemnification.....	13-7
13.6	Intellectual Property and Patent Rights.....	13-8
13.7	Publication of Study Results.....	13-9
13.8	Use of Agent/Device Provided by Industry Collaborator	13-10
14	Public relations.....	14-1
14.1	Authorized group representation.....	14-1
14.2	Public service.....	14-2
14.3	Dissemination of information to the general public	14-3
14.4	Confidentiality of patient information.....	14-5
15	Data sharing.....	15-1
15.1	Clinical Trial datasets.....	15-1
15.2	Large-scale genomic data sharing	15-3
15.2.1	Large-scale genomic data definition	15-3
15.2.2	Guidelines for availability of data sets.....	15-3
15.2.3	NIH data sharing policies.....	15-3
15.2.4	Alliance large-scale genomic studies.....	15-3
15.3	Request procedures.....	15-5
15.4	Regulatory considerations.....	15-6
15.5	Release conditions and disclaimer.....	15-7
15.6	Appeals process.....	15-8
15.7	Fees.....	15-9
16	Study monitoring and interim analyses.....	16-1
16.1	Study monitoring by the DSMB	16-1
16.1.1	Studies requiring DSMB monitoring	16-1
16.1.2	Function of the DSMB.....	16-1
16.2	Overview of DSMB procedures.....	16-3

**Alliance for Clinical Trials in Oncology
Policies and Procedure**

16.2.1	Confidentiality	16-3
16.2.2	Membership	16-3
16.2.3	Meetings	16-4
16.2.4	Recommendations.....	16-4
16.2.4.1	Study change for patient safety reasons.....	16-4
16.2.4.2	Study closure due to slow accrual.....	16-5
16.2.4.3	Study change for non patient safety reasons.....	16-5
16.2.4.4	Disagreement with Alliance DSMB Recommendations.....	16-5
16.2.5	Study modifications.....	16-6
16.2.6	Release of data & results.....	16-6
16.2.7	Presentation of results by intervention group.....	16-7
16.2.8	Phase 2/3 trials.....	16-7
16.2.9	Industry-supported studies.....	16-7
16.2.10	Conflict of interest.....	16-7
16.3	Monitoring phase 1 and 2 studies.....	16-8
16.3.1	Phase 1 studies	16-8
16.3.2	Phase 2 studies.....	16-8
17.	Quality Management.....	17-1
17.1.	Quality Management and Assurance Department.....	17-1
17.2.	Alliance Quality Monitoring and Management Committee (QMMC).....	17-2
17.2.1.	Studies requiring QMMC oversight.....	17-2
17.2.2.	Function of the QMMC.....	17-2
17.2.3.	Overview of the QMMC procedure.....	17-2
17.2.4.	Membership	17-2
17.2.5.	Review Process.....	17-2
17.2.6.	Recommendation/escalation process.....	17-3
17.3.	Regulatory Authority Inspection Readiness Activities.....	17-4
17.4.	Monitoring.....	17-5
17.4.1.	Central Data Monitoring.....	17-5
17.4.2.	On-site/remote Monitoring.....	17-5
17.5.	Institutional Audits.....	17-6
17.5.1.	History.....	17-6
17.5.2.	Quality assurance.....	17-6
17.5.3.	NCI audit participation.....	17-7
17.5.4.	Overview of Alliance auditing policies and procedures.....	17-8
17.5.5.	Scheduling audits.....	17-8
17.5.6.	Audit preparation by the institution	17-12
17.5.7.	Conduct of an Alliance audit.....	17-13
17.5.8.	Re-audits.....	17-35
17.5.9.	Audit review.....	17-35
17.6.	Institutional Network Performance Evaluation	17-39
17.7.	Institutional Probation.....	17-41